1. Abreu, S. L., 1983, Pharmacokinetics of rat fibroblast interferon, J. Pharmacol Exp. Ther.
226:197–220.
2. Aggarwal, B. B., Henzel, W. J., Moffat, B., Kohr, W. J., and Harkins, R. N., 1985, Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line, J. Biol. Chem.
260:2334–2344.
3. Ashwell, G., and Morell, A. G., 1974, The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins, Adv. Enz.
41:98–128.
4. Balkwill, F. R., Lee, A., Aldam, G., Moodie, E., Thomas, J. A., Tavernier, J., and Fiers, W., 1986, Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons, Cancer Res.
46:3990–3993.
5. Beutler, B., Mahoney, J., LeTrang, N., Pekala, P., and Cerami, A., 1985a, Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endo-toxin-induced RAW 264.7 cells, J. Exp. Med.
161: 984–995.